Abstract:Abstract Background Fistulising Crohn’s disease (fCD) affects up to 40% of people with Crohn’s disease (CD) over their lifetime, leading to perianal pain, faecal incontinence and sepsis. Despite its high prevalence, the burden of disease, treatment and “natural history” in the current biologic therapy era are poorly described. This study explored demographics, disease and treatment factors in a real-world cohort Methods The clinical quality registry (CQR) is created from deidentified data flowing into a registry during documentation in routine care. The CQR was interrogated in December 2022. People with CD with a care encounter in the last 14 months at one of 20 treating centres were included (n=3039). People with a current fistula were defined as those with an actively draining fistula on most recent clinical assessment, radiologic or endoscopic investigation. Previous fCD was defined as the prior presence of a fistula with most recent documentation showing resolution Results There were 3039 people with CD with a mean age of 43.1 years (SD +/- 16.23). 49% of the total CD cohort were female with a mean disease duration of 13.7 years (SD +/- 10.1). 532 (17.5%) people with CD had fCD documented in the CQR, with 220 current and 312 previous fCD. People with current or previous fCD were younger than those with no prior fistulising disease (40.5 & 39.6 vs 44.1, p=0.005 & p<0.001). Male gender was more commonly seen in those with current (58% p=0.022) or previous fCD (58% p=0.007) compared to those with no prior fCD (50% n=1270) People with current and previous fCD had higher rates of current biologic use compared to those with no prior fCD recorded (75.5% & 68.3% vs 48.9%, p<0.001 & p<0.001, respectively). Of those on biologic therapy, people with current or previous fistula were more likely to be on anti-TNF therapy (Adalimumab or Infliximab) compared to those with no history of fCD (85.5% & 82.2% vs 68.1%; p<0.001 & p<0.001 respectively). People with active or previous fCD were less likely to have ever been on steroid therapy compared to those without a history of fistulising disease (23.6%, 24.4% & 32.3%, p<0.001 & p<0.001) People with current or previous fCD had higher rates of CD-related hospital admissions compared to those without a history of fCD (5% & 6% vs 1.9%, p<0.001 and p<0.001 respectively). People with previous fistulising disease had higher rates of surgery within the last 12 months compared to people with no prior fCD (21.2% vs 13.3%, p<0.001) Conclusion People with current and previous fCD continue to experience higher hospitalisation rates for disease related complications and more frequently require surgical procedures. This highlights the importance of proactive management of fCD to reduce morbidity and avoidable healthcare utilisation

P627 Stopping Anti-Tumour Necrosis Factor (TNF) Therapy in Patients with Perianal Crohn’s Disease: Results from a Population-Based Study

Mo1918 – Can We Stop Anti-Tumour Necrosis Factor (ANTI-TNF) in Patients with Perianal Crohn’s Disease ? Results from a Population-Based Study

Discontinuation of Anti-Tumour Necrosis Factor Therapy in Patients with Perianal Fistulizing Crohn's Disease: Individual Participant Data Meta-Analysis of 309 Patients from 12 Studies

Outcomes of Perianal Fistulising Crohn's Disease Following Anti-TNFα Treatment Discontinuation

Significant Medical and Surgical Morbidity in Perianal Crohn’s Disease: Results from a Territory-Wide Study

P561 Risk of stoma formation in patients with Crohn’s perianal fistulas over a two decades period. A cohort study from a tertiary referral center

P611 Relation between AntiTNF levels during the induction and clinical and radiological outcomes in perianal Crohn ́s disease

Perianal Disease Onset Age is Associated with Distinct Disease Features and Need for Intestinal Resection in Perianal Crohn’s Disease: a Ten-Year Hospital-Based Observational Study in China

P574 Incidence and Indicators of Suboptimal Response to Tumour Necrosis Factor Antagonist Therapy in Chinese Patients with Inflammatory Bowel Disease: Results from the EXPLORE Study

P991 Serum anti-TNF levels correlate with tissue levels in perianal fistulising Crohn’s Disease

IDDF2020-ABS-0170 the Clinical Characteristics and Outcomes of Crohn’s Disease Patients with Perianal Disease Onset at Pediatric Versus Adult: a 10-Year Observational Study

P199 Analysis of Clinical Features of Asymptomatic Perianal Fistulizing Crohn’s Disease

Tumor Necrosis Factor Inhibitors May Have Limited Efficacy for Complex Perianal Fistulas Without Luminal Crohn's Disease

Strategies to Optimize Anti-tumor Necrosis Factor Therapy for Perianal Fistulizing Crohn's Disease: A Systematic Review

P946 Real life management of patients with active perianal fistulizing Crohn’s disease (ALERT-CD study)

P1129 Fistulising Crohn's Disease in a large Australasian cohort - Crohn's Colitis Cure (CCC) Data Insights Program

P546 Endoscopic findings related to the long-term response to anti-TNF-α antibody treatment in patients with Crohn's disease

Serum Anti-Tnf Levels Correlate with Tissue Levels in Perianal Fistulising Crohn's Disease

P769 Impact of discontinuation of anti-TNF therapy: A long term follow-up data of risks and predictors relapse in a large Indian cohort

Long-term Clinical Outcomes after the Discontinuation of Anti-Tnf Agents in Patients with Inflammatory Bowel Disease: a Meta-Analysis.

Prophylactic Antitubercular Therapy Is Associated With Accelerated Disease Progression in Patients With Crohn's Disease Receiving Anti-TNF Therapy: A Retrospective Multicenter Study